or Try an Advanced Search...

    Orphan Disease Stocks List

    Symbol Grade Name % Change
    FOLD F Amicus Therapeutics, Inc. -2.64
    CYCN D Cyclerion Therapeutics, Inc. 5.00
    EIGR F Eiger BioPharmaceuticals, Inc. 0.00
    FATE D Fate Therapeutics, Inc. 4.62
    SEEL F Seelos Therapeutics, Inc. -5.03
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Biotechnology Life Sciences Lysosomal Storage Disorder Lysosomal Storage Disorders Medicine Adult Stem Cell Biology Blood Cells Cardiomyopathy Central Nervous System Disease Cord Blood Diabetic Nephropathy Disease Disorders Enzyme Replacement Therapy Enzymes Fabry Disease Gaucher Disease Heart Failure

    Related ETFs - A few ETFs which own one or more of the above listed Orphan Disease stocks.

    Symbol Grade Name Weight
    WDNA D WisdomTree BioRevolution Fund 2.95
    PBE C PowerShares Dynamic Biotech & Genome 2.09
    LABD D Direxion Daily S&P Biotech Bear 3X Shares 2.05
    BBP C BioShares Biotechnology Products Fund 1.66
    XBI D SPDR S&P Biotech ETF 1.29
    View all Orphan Disease ETFs...
    Compare ETFs
    Compare LABD to XBI Compare PBE to BBP Compare WDNA to LABD

        Orphan Disease Stocks Recent News

        Date Stock Title
        May 10 FOLD Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript
        May 10 FATE Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...
        May 10 FOLD Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...
        May 10 FOLD Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
        May 10 FOLD Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
        May 9 FATE Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
        May 9 FATE Fate Therapeutics GAAP EPS of -$0.47 in-line, revenue of $1.93M beats by $0.67M
        May 9 FATE Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
        May 9 FOLD Amicus Therapeutics, Inc. (FOLD) Q1 2024 Earnings Call Transcript
        May 9 FATE Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
        May 9 FOLD Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
        May 9 FOLD Amicus Therapeutics reports mixed Q1 results; updates FY24 outlook
        May 9 FOLD Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
        May 8 FATE Fate Therapeutics Q1 2024 Earnings Preview
        May 8 FOLD Amicus Therapeutics Q1 2024 Earnings Preview
        May 8 FOLD Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
        May 6 FATE Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
        May 5 FATE Wall Street Breakfast: The Week Ahead
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Biotechnology Life Sciences Lysosomal Storage Disorder Lysosomal Storage Disorders Medicine Adult Stem Cell Biology Blood Cells Cardiomyopathy Central Nervous System Disease Cord Blood Diabetic Nephropathy Disease Disorders Enzyme Replacement Therapy Enzymes Fabry Disease Gaucher Disease Heart Failure
        Orphan Disease

        Orphan diseases are rare medical conditions that affect a small percentage of the population. They are often genetic in nature and can be life-threatening or chronically debilitating. Orphan diseases are often under-researched and underfunded, making it difficult to find treatments or cures.

        Browse All Tags